Capella Inc.
Surprise CE Mark for Stentys Xposition S stent
Stentys this week said it won a CE Mark ahead of schedule for its latest self-apposing coronary stent, a product that will be used with delivery system technology it acquired last June.
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.
Medtronic regulatory chief Susan Alpert to step down
Medtronic Inc.’s (NYSE:MDT) chief regulatory affairs officer Susan Alpert will join her boss, William Hawkins, on Retirement Row this year, according to company officials.
Alpert, who has held the senior vice president and chief regulatory officer positions at Medtronic since 2005, had a similar role at C.R. Bard (NYSE:BCR) before joining MDT and is also a former director of the FDA’s Office of Device Evaluation .
Medtronic “internal cast” effective on cancer patients’ spinal fractures | Research roundup
Here’s a roundup of recent clinical trial and scientific study news:
Cappella closes $14.3 million round | Funding roundup
Here’s a roundup of the latest dealflow and investment news:
pSivida touts latest diabetic macular edema study results | Research roundup
Here’s a roundup of recent clinical trial and scientific study news:
Delcath CEO Hobbs takes top spot on Capella’s board
Eamonn Hobbs took over as board chairman for Irish stent-maker Capella Inc.
Hobbs is CEO of Delcath Systems Inc. (NSDQ:DCTH), a New York-based manufacturer of arterially administered cancer treatments, and was CEO and co-founder of AngioDynamics (NSDQ:ANGO). Hobbs fills the position of former Capella chairman Dr. Wolfgang Oster, a managing partner at PolyTechnos Venture-Partners GmbH.
